Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Fujian Shengdi Pharmaceutical Co: Clinical Trials & FDA Approval Profile

Fujian Shengdi Pharmaceutical Co (Global / Institutional) sponsors 37 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 21 active protocols (11 recruiting now), 13 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)218 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Fujian Shengdi Pharmaceutical Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)37
Active Pipeline (Recruiting Now)21 (11)
Completed vs Stopped Early13 / 0 (0.0%)
Median Closed Actual Enrollment218 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Fujian Shengdi Pharmaceutical Co
Hospital Research SiteLocationShared Protocols
Shanghai Chest HospitalShanghai2
Nanjing Drum Tower HospitalNanjing2

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Fujian Shengdi Pharmaceutical Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05881837A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without DiabetesPhase IICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Fujian Shengdi Pharmaceutical Co Interactive Dossier, benchmark peers in Endocrinology, Obesity, and Metabolic, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI